To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.

Pfizer

Status and phase: Completed; Phase 3

Conditions: Neuralgia

Treatments: Drug: Pregabalin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00150436

1008-198

Details and patient eligibility

About

To evaluate long-term safety and efficacy of pregabalin in patients with postherpetic neuralgia.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have met the inclusion criteria for preceding double-blind BID study in postherpetic neuralgia
• Must have received pregabalin/placebo under double-blind conditions for a minimum of 3 weeks.

Exclusion criteria

• Patients cannot participate if they experienced a serious adverse event during preceding double-blind BID study which was determined to be related to the study medication.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)